Enzastaurin (LY317615)

Catalog No.S1055

Enzastaurin (LY317615) Chemical Structure

Molecular Weight(MW): 515.61

Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.

Size Price Stock Quantity  
In DMSO USD 109 In stock
USD 120 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  •  

    The protein kinase C (PKC)–specific inhibitor enzastaurin
    induces apoptosis of lupus B cells and prevents lupus development
    in Sle mice. C, Levels of serum IgG anti–double-stranded DNA
    (anti-dsDNA) and antihistone/anti-dsDNA autoantibodies from
    vehicle-treated control mice and enzastaurin-treated mice, as analyzed
    by enzyme-linked immunosorbent assay. Bars in A–C show the mean 
    SD of 3 independent experiments. D, Representative immunofluorescent
    images of IgG deposition (top) and glomeruli (bottom) in kidney
    sections from Sle1.Sle3 mice treated with vehicle or enzastaurin. Original
    magnification  20 (top);  40 (bottom). PAS  periodic acid–Schiff.

    Arthritis Rheum 2013 65, 1022-31. Enzastaurin (LY317615) purchased from Selleck.

     

    The protein kinase C (PKC)–specific inhibitor enzastaurin
    induces apoptosis of lupus B cells and prevents lupus development
    in Sle mice. A, Effect of enzastaurin on apoptosis of lupus B cells.
    Purified splenic B cells were treated with anti-IgM antibody in the
    presence or absence (control) of enzastaurin for 48 hours and analyzed
    with an annexin V detection kit. The fractions of annexin V–positive
    (apoptotic) cells in the samples treated with only anti-IgM (control)
    are set at 1. B, Sensitivity of human 9G4-positive and 9G4-negative
    B cells to PKC inhibition. Purified splenic B cells were treated with
    enzastaurin for 24 hours. The apoptotic fractions from untreated
    samples are set at 1. Results are representative of 2 independent
    experiments.

    Arthritis Rheum 2013 65, 1022-31. Enzastaurin (LY317615) purchased from Selleck.

  •  

    PKC II contributes to the depolarization-induced enhancement of KCNQ currents. C, PKC  inhibitor enzastaurin (2 μM) significantly reduced the depolarization (ND96-K)-induced increase in membrane PKC II levels. D, enzastaurin blocked the depolarization (0 mV)-induced increase of KCNQ2/Q3 current. **, p < 0.01 compared with the control.

     

    J Biol Chem 2011 286, 39760-7. Enzastaurin (LY317615) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.
Targets
PKCβ [1]
(Cell-free assay)
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCε [1]
(Cell-free assay)
6 nM 39 nM 83 nM 110 nM
In vitro

Enzastaurin application results in a marked dose-dependent inhibition of growth in all MM cell lines investigated, including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266, with IC50 from 0.6-1.6 μM. Enzastaurin direct impacts human tumor cells, inducing apoptosis and suppressing proliferation in cultured tumor cells. Enzastaurin also suppresses the phosphorylation of GSK3βser9, ribosomal protein S6S240/244, and AKTThr308 while having no direct effect on VEGFR phosphorylation. [1] Enzastaurin increases apoptosis in malignant lymphocytes of CTCL. When combined with GSK3 inhibitors, enzastaurin demonstrated an enhancement of cytotoxicity levels. Treatment with a combination of enzastaurin and the GSK3 inhibitor AR-A014418 led to increased levels of β-catenin total protein and β-catenin-mediated transcription. Blocking of β-catenin-mediated transcription or small hairpin RNA (shRNA) knockdown of β-catenin induced the same cytotoxic effects as that of enzastaurin plus AR-A014418. Additionally, treatment with enzastaurin and AR-A014418 decreased the mRNA levels and surface expression of CD44. [2]

In vivo Treatment of xenografts with Enzastaurin and radiation produced greater reductions in density of microvessels than either treatment alone. The decrease in microvessel density corresponded to delayed tumor growth. [3]

Protocol

Kinase Assay
+ Expand

Kinase inhibition assays:

The inhibition of PKCβII, PKCα, PKCε, or PKCγ activity by enzastaurin is determined using a filter plate assay format measuring 33P incorporation into myelin basic protein substrate. Reactions are done in 100 μL reaction volumes in 96-well polystyrene plates with final conditions as follows: 90 mM HEPES (pH 7.5), 0.001% Triton X-100, 4% DMSO, 5 mM MgCl2, 100 μM CaCl2, 0.1 mg/mL phosphatidylserine, 5 μg/mL diacetyl glyerol, 30 μM ATP, 0.005 μCi/μL 33ATP, 0.25 mg/mL myelin basic protein, serial dilutions of enzastaurin (1-2,000 nM), and recombinant human PKCβII, PKCα, PKCε, or PKCγ enzymes (390, 169, 719, or 128 pM, respectively). Reactions are started by addition of the enzyme and incubated at room temperature for 60 minutes. They are then quenched with 10% H3PO4, transferred to multiscreen anionic phosphocellulose 96-well filter plates, incubated for 30 to 90 minutes, filtered and washed with 4 volumes of 0.5% H3PO4 on a vacuum manifold. Scintillation cocktail is added and plates are read on a Microbeta scintillation counter. IC50 values are determined by fitting a three-variable logistic equation to the 10-point dose-response data using ActivityBase 4.0.
Cell Research
+ Expand
  • Cell lines: HCT116 and U87MG cells
  • Concentrations: 0.3-4 μM
  • Incubation Time: 72 hours
  • Method:

    Induction of apoptosis by enzastaurin is measured by nucleosomal fragmentation and terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) and staining in HCT116 and U87MG cell lines. Briefly, 5 × 103 cells are plated per well in 96-well plates (1% FBS-supplemented media conditions), incubated with or without Enzastaurin for 48 to 72 hours. The absorbance values are normalized to those from control-treated cells to derive a nucleosomal enrichment factor at all concentrations as per the manufacturer's protocol. The concentrations studied ranges from 0.1 to 10 μM. In situ TUNEL staining is assayed with the In situ Cell Death Detection, Fluorescein kit. Cells (7.5 ?104) are plated per well in 6-well plates and incubated 72 hours in 1% FBS-supplemented media ?Enzastaurin. Fluorescein-labeled DNA strand breaks are detected with the BD epics flow cytometer. Ten thousand, single-cell, FITC-staining events are collected for each test.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Athymic nude mice; Mouse besring human MM tumors
  • Formulation: 10% acacia in water; dissolved in 100% ethanol and diluted 1:10 in D5W
  • Dosages: 75 mg/kg twice daily; 30 mg/kg twice daily
  • Administration: By gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 30 mg/mL (58.18 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 515.61
Formula

C32H29N5O2

CAS No. 170364-57-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01432951 Active, not recruiting Solid Tumor|Lymphoma, Malignant Eli Lilly and Company November 2011 Phase 1
NCT01388335 Completed Solid Tumor|Lymphoma, Malignant Eli Lilly and Company August 2011 Phase 1
NCT00685633 Withdrawn Prostate Cancer Eastern Cooperative Oncology Group|National Cancer Institute (NCI) December 2008 Phase 2
NCT00744991 Completed Cutaneous T-Cell Lymphoma Eli Lilly and Company September 2008 Phase 2
NCT00718419 Completed Waldenstroms Macroglobulinemia|Multiple Myeloma Eli Lilly and Company July 2008 Phase 2
NCT00709995 Active, not recruiting Metastatic Renal Cell Carcinoma Eli Lilly and Company June 2008 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

PKC Inhibitors with Unique Features

Related PKC Products

Tags: buy Enzastaurin (LY317615) | Enzastaurin (LY317615) supplier | purchase Enzastaurin (LY317615) | Enzastaurin (LY317615) cost | Enzastaurin (LY317615) manufacturer | order Enzastaurin (LY317615) | Enzastaurin (LY317615) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID